A significant cause of these off-target effects is a seven-nucleotide region known as the seed region, located within the guide strand of the siRNA, which is critical for target recognition.

RNA interference is a conserved biological response to double-stranded RNA that regulates gene expression. The response is mediated by small interfering RNAs (siRNAs), which guide the ...

In liver, lipid nanoparticles (LNPs) were first used to deliver patisiran, currently the only siRNA drug on the market that uses this technology platform. The animal POC studies of LNP-mediated siRNA ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

The alternative text for this image may have been generated using AI. On 10 August 2018, the US Food and Drug Administration (FDA) inducted RNAi drugs into medicine by approving patisiran (Onpattro; ...

Yes-associated protein (YAP), encoded by Yes1-associated transcriptional regulator (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ), encoded by WW ...

A formamide modification (yellow) to a therapeutic agent siRNA (blue) prevents siRNA to bind to non-target mRNA, which allows for treatment with less side effects. Small interfering RNA (siRNA) drugs ...